SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

GoldCoin is experiencing fragmented discussions, with sentiment largely driven by its historical identity as a speculative asset and ongoing debates comparing it to gold and Bitcoin as stores of value. Traders are divided between those monitoring technical patterns and those speculating on potential future network developments, while others warn against conflating it with gold bullion or related ETFs.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive topline Phase 3 IZAR-1 trial results, though shares faced downward pressure as the data were perceived as competitive rather than demonstrating clear superiority. Traders are currently debating the company's valuation, the impact of continued share dilution, and the long-term potential of its sonelokimab therapy as the company progresses toward a BLA submission for hidradenitis suppurativa.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Investors are currently focused on Internet Computer's technological developments, such as the Caffeine AI initiative and the growth of its decentralized cloud ecosystem, while debating its long-term potential versus concerns over historical price performance and tokenomics. Sentiment remains divided between those accumulating for the long term based on infrastructure utility and those expressing frustration over sustained downward price pressure.

Polygon

Polygon (POL) is currently experiencing high volatility, with the community divided between frustration over its underperformance during broader crypto rallies and optimism regarding its transition toward a payment-focused infrastructure. While some traders view recent strategic shifts and institutional partnerships as catalysts for a long-term recovery, many participants express disappointment, frequently citing token dilution and persistent downward pressure.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as traders debate its potential for a major price move driven by its limited supply and the institutional adoption of its DeFi protocol. While some community members remain optimistic about a breakout, discussion is fragmented by significant skepticism regarding recent price action and comparisons to rival protocols.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as members of the community highlight recent network upgrades, including the launch of v5.0 and post-quantum security features, while others debate whether the asset is currently in an accumulation phase or a long-term decline.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors monitor the company's progress toward regulatory milestones for its lead CRISPR-based candidate, Lonvo-z, with many noting the significance of its non-dilutive financing and potential for future commercialization. While some traders express optimism regarding the company's gene-editing platform and institutional support, others highlight concerns about cash burn, potential dilution, and the competitive biotech landscape.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is trending as traders capitalize on the high volatility and rebound momentum of the memory sector, with many discussing leveraged strategies and the stock's significant price swings. Community sentiment remains largely focused on technical setups, cyclical recovery, and anticipation of upcoming company earnings.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is seeing significant momentum and bullish sentiment driven by its strong performance as a privacy-focused alternative to Bitcoin and the recent introduction of the Grayscale Zcash ETF. Traders are closely monitoring this price appreciation, with many debating the sustainability of the rally and potential price targets while highlighting the role of institutional involvement and supply scarcity.

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties, with a focus on silver and gold production in North America. It owns and operates producing mines in Mexico, including the Santa Elena Silver & Gold Mine, the Los Gatos Silver Mine, the San Dimas Silver & Gold Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA, which is currently in the process of restarting. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as traders react to extreme price volatility and a disconnect between the miner's performance and silver spot prices. While some community members view recent weakness as a strategic buying opportunity citing long-term demand for physical silver, others express frustration over continued price suppression and skepticism regarding technical breakouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

S&P 500, Nasdaq And Dow Close At Record Highs Amid Positive Reports Of US-Iran Ceasefire Negotiations —  IBM, SNOW, CZR, AKTX, LLY In Focus

Equity

U.S. and Iranian negotiators agreed on a 60-day memorandum of understanding to extend the ceasefire, media reports suggested.

AKTX Stock Shoots 50% Higher To Head Toward Best Month In Nearly 11 Years – What’s Fueling This Super Rally?

Akari Therapeutics’ CEO Abizer Gaslightwala highlighted the potential of the company’s proprietary platform to treat cancer ahead of ASCO 2026.

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.read more...

Why Akari Therapeutics Stock Is Falling On Tuesday?

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.read more...

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Akari Therapeutics shares are surging after preclinical data showed AKTX101 synergized with KRAS inhibition in pancreatic cancer models.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside 

Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab tests on pancreatic cancer cells that carry a common KRAS mutation.


The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Why Akari Therapeutics Stock Is Surging On Thursday?

Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new European patent for its PH1 ADC payload.read more...

This account has been verified as an official AKTX representative.

Verified Account

Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Bullish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$11.47
Prev Close	$10.84
Open	$10.41
Dividend Yield	0.00%
50-Day Moving Average	$9.60
Beta	0.58
Avg. Volume	64,530.18
PE Ratio	-0.04

52-Week High	$49.60
52-Week Low	$3.02
Market Capitalization	$20.08M
EPS (Annual)	N/A
Price to Book	1.08
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

AKTX Fundamentals